ArticleMultiple sclerosis journal - experimental, translational and clinical

Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study.

B Khatri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.